GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanopharmaceutics Inc (OTCPK:TGRP) » Definitions » Total Stockholders Equity

Nanopharmaceutics (Nanopharmaceutics) Total Stockholders Equity : $-8.30 Mil (As of Sep. 2018)


View and export this data going back to 2016. Start your Free Trial

What is Nanopharmaceutics Total Stockholders Equity?

Nanopharmaceutics's Total Stockholders Equity for the quarter that ended in Sep. 2018 was $-8.30 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Nanopharmaceutics's Book Value per Share for the quarter that ended in Sep. 2018 was $-0.05. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Nanopharmaceutics's Debt-to-Equity for the quarter that ended in Sep. 2018 was -0.00.

Nanopharmaceutics Total Stockholders Equity Historical Data

The historical data trend for Nanopharmaceutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanopharmaceutics Total Stockholders Equity Chart

Nanopharmaceutics Annual Data
Trend Dec15 Dec16 Dec17
Total Stockholders Equity
- -6.74 -8.08

Nanopharmaceutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.03 -8.08 -8.52 -8.39 -8.30

Nanopharmaceutics  (OTCPK:TGRP) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Nanopharmaceutics's Book Value per Share for the quarter that ended in Sep. 2018 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-8.297-0)/163.329
=-0.05

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Nanopharmaceutics's Debt-to-Equity for the quarter that ended in Sep. 2018 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.013 + 0) / -8.297
=-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanopharmaceutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Nanopharmaceutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanopharmaceutics (Nanopharmaceutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanopharmaceutics Inc (OTCPK:TGRP) » Definitions » Total Stockholders Equity
Comparable Companies
MIII TSE:5363 TSE:7721 TSE:5821 TSX:AEF SDOIA DFM:GGICO SAU:2120 ABWN COL:RICH.N0000 CNAC MIL:SPRT XSGO:QUEMCHI TSE:3353 COL:VONE.N0000 XPAE:APIC MIL:CRS ELEC ATH:MIG XCNQ:MARI
Traded in Other Exchanges
N/A
Address
14120 NW 126 Terrace, Alachua, FL, USA, 32615
Website
https://www.nanopharmaceutics.com
Nanopharmaceutics Inc is a clinical-stage specialty pharmaceutical company. It is engaged in developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. The company's pipeline products include Triapine, Ammonium Tetrathiomolybdate, and Aza-TdC targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3 targeting CNS; and Ramoplanin and NanoDOX.